Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardax, Inc. stock logo
CDXI
Cardax
$0.00
$0.00
$0.00
N/A-1.51N/AN/A
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
$0.00
$0.00
$0.00
N/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
$0.11
$0.11
$0.06
$8.60
N/AN/AN/A32,900 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
VGLS
VG Life Sciences
$0.00
$0.00
$0.00
$0.00
$2.11M1.758.28 million shs760,046 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardax, Inc. stock logo
CDXI
Cardax
0.00%0.00%0.00%-50.00%-50.00%
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
0.00%0.00%0.00%0.00%-80.00%
MLNTQ
Melinta Therapeutics
0.00%0.00%0.00%0.00%0.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
VGLS
VG Life Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardax, Inc. stock logo
CDXI
Cardax
N/AN/AN/AN/AN/AN/AN/AN/A
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardax, Inc. stock logo
CDXI
Cardax
0.00
N/AN/AN/A
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
0.00
N/AN/AN/A
MLNTQ
Melinta Therapeutics
0.00
N/AN/AN/A
NSPX
Inspyr Therapeutics
0.00
N/AN/AN/A
VGLS
VG Life Sciences
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardax, Inc. stock logo
CDXI
Cardax
N/AN/AN/AN/AN/AN/A
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
N/AN/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardax, Inc. stock logo
CDXI
Cardax
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
N/AN/A0.00N/AN/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A
VGLS
VG Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardax, Inc. stock logo
CDXI
Cardax
N/AN/AN/AN/AN/A
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
N/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardax, Inc. stock logo
CDXI
Cardax
N/AN/AN/A
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
N/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/A
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
VGLS
VG Life Sciences
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardax, Inc. stock logo
CDXI
Cardax
10800,000566,000Not Optionable
Critical Outcome Technologies, Inc. stock logo
COTQF
Critical Outcome Technologies
N/AN/AN/ANot Optionable
MLNTQ
Melinta Therapeutics
290N/AN/ANot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable
VGLS
VG Life Sciences
121.10 billionN/ANot Optionable

Recent News About These Companies

VGLS VG Life Sciences Inc. - Seeking Alpha
VG Life Sciences Inc.
VG Life Sciences, Inc. Increases Authorized Shares
VG Life Sciences Inc. (VGLS)
VG Life Sciences Inc VGLS
Report warns of 'oversupply' of life sciences real estate
VGLS VG Life Sciences Inc.
Cardax stock logo

Cardax OTCMKTS:CDXI

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

Critical Outcome Technologies stock logo

Critical Outcome Technologies OTCMKTS:COTQF

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Melinta Therapeutics OTCMKTS:MLNTQ

$0.11 0.00 (0.00%)
As of 04/20/2020

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

VG Life Sciences OTCMKTS:VGLS

$0.0001 0.00 (0.00%)
As of 03:15 PM Eastern

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.